NASDAQ · OBIO
Healthcare · Biotechnology
$5.99
Up+$0.21 (+3.63%)
Updated Oct 29, 2026, 11:54 AM
SID Score
6.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · OBIO
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 28, 2026
OBIO closed at $5.99 after 21 trading sessions, down 3.70% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 28, 2026 | $5.76 | $6.03 | $5.68 | $5.99 | 425.57K |
| Oct 27, 2026 | $5.56 | $5.8418 | $5.52 | $5.78 | 376.78K |
| Oct 26, 2026 | $5.58 | $5.655 | $5.52 | $5.55 | 242.66K |
| Oct 23, 2026 | $5.46 | $5.66 | $5.39 | $5.59 | 262.03K |
| Oct 22, 2026 | $5.72 | $5.7894 | $5.43 | $5.47 | 390.88K |
| Oct 21, 2026 | $5.83 | $5.865 | $5.57 | $5.805 | 485.98K |
| Oct 20, 2026 | $5.65 | $6.17 | $5.53 | $5.82 | 992.78K |
| Oct 19, 2026 | $5.49 | $5.73 | $5.415 | $5.65 | 226.59K |
| Oct 16, 2026 | $5.75 | $5.87 | $5.37 | $5.45 | 473.66K |
| Oct 15, 2026 | $5.68 | $5.85 | $5.66 | $5.74 | 253.38K |
| Oct 14, 2026 | $5.70 | $5.86 | $5.60 | $5.64 | 222.88K |
| Oct 13, 2026 | $5.87 | $5.87 | $5.71 | $5.72 | 204.82K |
| Oct 12, 2026 | $5.93 | $5.99 | $5.39 | $5.91 | 237.99K |
| Oct 9, 2026 | $5.73 | $5.965 | $5.56 | $5.95 | 229.32K |
| Oct 8, 2026 | $5.75 | $5.83 | $5.51 | $5.73 | 241.88K |
| Oct 7, 2026 | $5.79 | $5.859 | $5.64 | $5.66 | 241.25K |
| Oct 6, 2026 | $6.05 | $6.12 | $5.82 | $5.84 | 213.12K |
| Oct 5, 2026 | $5.89 | $6.09 | $5.7898 | $6.03 | 284.8K |
| Oct 2, 2026 | $6.40 | $6.44 | $5.77 | $5.95 | 421.09K |
| Oct 1, 2026 | $6.27 | $6.50 | $6.23 | $6.35 | 389.94K |
| Sep 30, 2026 | $6.09 | $6.29 | $6.00 | $6.22 | 277.39K |
The latest Smart Investors Daily articles mentioning OBIO.
Company
Market Activity
Research & News
OBIO research
Company profile and research snapshot.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 23, 2026 | Chardan Capital | Buy | — |
| Sep 15, 2026 | B. Riley Securities | Buy | — |
| Sep 10, 2026 | BTIG | Buy | — |
| Aug 11, 2026 | Piper Sandler | Overweight | — |
| May 19, 2026 | B. Riley Securities | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 23, 2026
Gainers Pomdoctor (NASDAQ:POM) shares rose 25.6% to $1.47 during Friday's after-market session. The market value of their outstanding shares is at $8.3 million. GeneDx Holdings (NASDAQ:WGS) shares rose 8.72% to
Yahoo · Oct 22, 2026
Company leadership, leading cardiologists and trial investigators to discuss unmet patient needs, BACKBEAT and Virtue pivotal trials, and upcoming milestones; in person in New York City and via live webcastNEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an R&D Day on Nove
Yahoo · Oct 20, 2026
Investing.com -- OpenAI has acquired Orchestra Bio, a startup that builds AI agents to help pharmaceutical companies manage drug development, Axios reported on Tuesday .
SeekingAlpha · Oct 15, 2026
Orchestra BioMed (OBIO) stock is rated Hold at $5.72 ahead of pivotal hypertension pacemaker trial data (Q2 2027). See here for more details.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OBIO.
